Quinolone Antibiotics: The Development of Moxifloxacin

Petersen, Uwe

doi:10.1002/3527608001.ch17

Cited by 7 publications

(5 citation statements)

References 136 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Actually, quinoline antibiotics constructed of the quinoline ring can be the most spectacular example of the potential efficiency of this system in medicinal chemistry [183] while a quinine molecule that also contains a quinoline moiety proves Nature's preference for the system. The quinoline scaffold can also be found in many classes of other biologically active compounds that are used as antifungals, antibacterials and antiprotozoic drugs as well as antituberculotic agents.…”

Section: Preferential Arrangement Of Azanaphtha-lenesmentioning

confidence: 99%

Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold

Polański

Kurczyk²,

Bąk³

et al. 2012

CMC

View full text Add to dashboard Cite

The concept of privileged structures/substructures (PS) is the idea that certain structural features produce biological effects more often than others. The PS method can be seen as an offspring of fragonomics, which is based on recent experimental measurements of protein-ligand interactions. If PS prove to be true, then chemical motives that enrich biological activity can be used when designing new drugs. However, PS remain controversial because we cannot be sure whether the excess of active structures does not result from an abundance in chemical libraries. In this review, we will focus, in particular, on the preferential organization of azanaphthalene scaffolds (AN) in drugs and natural products (NP), which are preferred by Nature in evolution. We will show that knowledge discovery in molecular databases can reveal interesting time-trends profiles for important classes of potentially privileged scaffolds. The chemical library of AN is dominated by monoaza-compounds, among which quinoline appears to be the most frequently investigated scaffold; however; more sophisticated database mining seems to indicate different PS patterns within the AN scaffold family.

show abstract

Section: Preferential Arrangement Of Azanaphtha-lenesmentioning

confidence: 99%

Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold

Polański

Kurczyk²,

Bąk³

et al. 2012

CMC

View full text Add to dashboard Cite

show abstract

“…As a result of these two major omissions, the ICI work has been essentially unrecognized as an major independent cocontribution to the discovery of an important class of antibacterials. Over the decades, only brief statements from a handful of researchers have noted ICI’s contributions to the quinolone antibacterial class. ,− …”

Section: Sterling: a “Lean” Record For Citation Of Relevant Prior Artmentioning

confidence: 99%

Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”

2015

View full text Add to dashboard Cite

Published descriptions of the specific lines of research leading to the discovery of therapeutically important medicines, especially major new class medicines, have long provided value to the biopharmaceutical community as models of success, often influencing the strategies and methods of subsequent drug research. Quinolone antibacterials represent one of medicine's most important classes of anti-infective agents; yet in contrast to many other classes of anti-infectives, astonishingly few details concerning the origin of the class or the rationale leading to the selection of the first clinical agent, nalidixic acid, were ever published by the discoverers. Moreover, earlier disclosures of an independent discovery of the quinolone class of antibacterials have been almost entirely overlooked by the scientific literature. This review brings together all the available information from primary literature sources relating to both discoveries and provides for the first time a much fuller, if still partially speculative, story of the earliest years of this important class of drugs.

show abstract

“…MFX is used to treat many infections including, chronic bronchitis, acute bacterial sinusitis, community acquired pneumonia, respiratory tract infections, cellulitis, anthrax, intraabdominal infections, endocarditis, meningitis, and tuberculosis. In ophthalmology, MFX is approved for the treatment of conjunctival infections caused by susceptible bacteria [9][10][11][12][13].…”

Section: Graphical Abstract Introductionmentioning

confidence: 99%